| Literature DB >> 31191901 |
Caspian M Sawczak1,2, Alexander J Barnett3,4, Melanie Cohn1,2.
Abstract
Hallucinations are common in Parkinson's disease (PD). Based on functional brain MRI data, hallucinations are proposed to result from alterations in the dorsal attention network (DAN), ventral attention network (VAN), and default mode network. Using structural MRI data from Parkinson's Progression Markers Initiative (PPMI), we examined cortical thickness in these networks in PD patients with (n=30) and without (n=30) minor hallucinations who were matched on multiple clinical characteristics (e.g., age, sex, education, cognitive diagnosis, MoCA score, medication, disease duration, and severity) as well as healthy controls (n=30) matched on demographic variables. Multivariate analyses revealed mild hallucinations to be associated with thicker cortex in the DAN and VAN, and these effects were driven by the left superior precentral sulcus and postcentral sulcus for the DAN and by the right insular gyrus for the VAN. While these findings may seem at odds with prior work showing grey matter reductions, our patients are in earlier stages of the disease than those in other studies. This is consistent with an inverted U-shape pattern of cortical thickness alterations in other neurodegenerative diseases and warrants further investigations in longitudinal studies tracking brain correlates of PD psychosis progression.Entities:
Year: 2019 PMID: 31191901 PMCID: PMC6525808 DOI: 10.1155/2019/5351749
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Demographic and clinical characteristics.
| HC ( | PDnH ( | PDMH ( |
| Post hoc | ||||
|---|---|---|---|---|---|---|---|---|
| Demographics | ||||||||
| Age (years) | 63.2 | (9.5) | 62.7 | (8.1) | 63.7 | (9.7) | 0.919 | |
| Male, | 19 | (63) | 19 | (63) | 19 | (63) | ||
| Education (years) | 16.0 | (2.9) | 15.1 | (3.1) | 15.6 | (2.9) | 0.505 | |
|
| ||||||||
| Clinical | ||||||||
| Years since diagnosis | — | — | 1.7 | (1.1) | 2.3 | (1.4) | 0.094 | |
| MDS-UPDRS Part III | — | — | 21.0 | (10) | 25.7 | (11.3) | 0.097 | |
| Hoehn and Yahr, median (range) | — | — | 2 | (1–3) | 2 | (1–3) | 0.347 | |
| Dyskinesia present, | — | — | 1 | (3) | 0 | (0) | 0.313 | |
| REM sleep behaviour disorder, | — | — | 9 | (30) | 15 | (50) | 0.114 | |
| Medication for PD, | — | — | 12 | (41) | 17 | (57) | 0.240 | |
| Levodopa, | — | — | 7 | (23) | 12 | (40) | 0.165 | |
| DA agonist, | — | — | 2 | (7) | 6 | (20) | 0.129 | |
| Other, | — | — | 4 | (13) | 7 | (23) | 0.317 | |
| LEDD (mg) | — | — | 370.2 | (225.5) | 410.9 | (273.9) | 0.675 | |
| Antipsychotic medication (quetiapine), | — | — | 0 | (0) | 1a | (3) | 0.313 | |
| Duration of hallucinations (years) | — | — | — | — | 1.23 | (0.66) | — | |
|
| ||||||||
| Cognition | ||||||||
| Cognitive state (intact: MCI) | 30 : 0 | 20 : 10 | 20 : 10 | — | ||||
| MoCA | 28.1 | (1.8) | 26.5 | (2.3) | 25.7 | (2.5) | <0.001 | HC > PDnVH and PDMH |
Notes: demographic, clinical, and cognitive characteristics of our sample. Mean and standard deviation (parentheses) except where otherwise noted. ANOVAs were conducted for each measure and, if significant (p ≤ 0.05), group differences were ascertained through post hoc testing. DA = dopamine; LEDD = levodopa equivalent daily dosage; MCI = mild cognitive impairment; MoCA = Montreal Cognitive Assessment. aQuetiapine 25 mg initiated 6 years prior to the scan date to treat anxiety.
Figure 1Group difference in cortical thickness. (a) Linear contrasts for each PLS network analysis. (b) Central MNI coordinates of the FreeSurfer parcellations and bootstrap ratios (BSRs) for all ROIs within the DAN and VAN. Asterisks indicate the most salient ROIs (BSR ≥ 2) contributing to each pattern. (c) Most salient ROIs in the DAN (dark blue = left frontal eye fields; light blue = left inferior parietal lobule) and VAN (orange = right insula). DMN is not depicted as no significant latent variable was found.